Co-Diagnostics, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 11, 2022 and accepted by EDGAR at Aug 11, 2022, 16:06 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $5.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $27.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $915.4k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $4.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $4.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $23.5m | us-gaap:GrossProfit |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $3.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $7.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | $5.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-04-01 to 2022-06-30 | −$741.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $644.6k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | $9.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | $0.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | $0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 32,472,251 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 33,253,612 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | $9.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $904.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2022-01-01 to 2022-06-30 | $2.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-06-30 | $86.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $114.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $160.8m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $6.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $16.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $144.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-022072. Last ingested by Listed: Nov 4, 2026, 18:23 ET. Listed shows no prices and gives no investment advice.